Bruker Announces Acquisition of SkyScan
News Apr 09, 2012
Bruker Corporation has announced that it has acquired all of the shares of SkyScan N.V., a scientific instruments company located near Antwerp, Belgium. Financial details were not disclosed.
For the remainder for 2012, the acquisition of SkyScan is expected to add approximately $13 million to Bruker's revenue and to be accretive to EPS by about $0.01.
SkyScan's revenue is derived approximately 50% from materials science and 50% from life science and preclinical imaging applications.
SkyScan develops, manufactures and distributes worldwide advanced, high-resolution micro computed tomography (CT) systems for three-dimensional (3D) X-ray imaging.
SkyScan's micro-CT instruments can be configured for numerous applications in materials research and in the life sciences, including in vivo preclinical animal imaging, in vitro bone and soft tissue imaging, 3D imaging of electronic components, synthetic materials, new devices such as microsensors and cardio-stimulators, geological samples, fuel cell components, ceramics, and more.
Following the acquisition, the company has been renamed Bruker microCT N.V., and will continue to operate from the company-owned premises in Belgium under its previous management.
The new Bruker microCT business will continue to produce all micro-CT instruments under the SkyScan brand, and will provide enhanced global support for the installed worldwide base of SkyScan.
With global Bruker distribution and customer service capabilities for materials research, preclinical imaging, and SEM accessories, the Bruker microCT business is now well positioned to drive the further profitable growth of the SkyScan 3D micro-CT imaging products.
In addition, most successful SkyScan distributors will be able to continue to distribute SkyScan products in their countries or market segments.
Bruker intends to invest in additional micro-CT applications and demo centers to further enhance customer collaborations and support worldwide.
Dr. Alexander Sasov, founder and CEO of the former SkyScan company, and now Managing Director and CEO of Bruker microCT, commented: "We have been looking for a strong and competent strategic partner to continue the rapid growth that SkyScan has enjoyed over many years. I am very glad that with the strong Bruker brand and the additional worldwide Bruker distribution channels and support network, we have found exactly what we were looking for to drive our micro-CT business to the next level of success."
Frank Laukien, PhD, President and CEO of Bruker Corporation, added: "We are excited to have Alexander Sasov and his capable SkyScan team join us, adding in-depth 3D X-ray micro-CT imaging experience to Bruker. We are impressed by the portfolio of high-performance SkyScan products which fit nicely into our global materials research and preclinical imaging distribution channels, and which complement our other X-ray analysis and preclinical MRI products. The Bruker microCT team shares our philosophy of innovation, quality and customer support excellence."
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE
Survival Trait Evolution Shown in 54 Million-Year-Old Sea TurtleNews
High-resolution analytical techniques of pigment, beta-keratin and muscle proteins from a 54 million-year-old sea turtle hatchling revealed that a pigment-based survival trait common to modern sea turtles evolved at least 54 million years ago.READ MORE